Brind.
  1. AbbVie's product portfolio was bolstered by the acquisition of Allergan, while Humira sales faced erosion due to patent loss and biosimilar competition.
  2. AbbVie's product portfolio was bolstered by the acquisition of Allergan, while Humira sales faced erosion due to patent loss and biosimilar competition.
  3. AbbVie's product portfolio was bolstered by the acquisition of Allergan, while Humira sales faced erosion due to patent loss and biosimilar competition.
  4. AbbVie's product portfolio was bolstered by the acquisition of Allergan, while Humira sales faced erosion due to patent loss and biosimilar competition.

AbbVie's product portfolio was bolstered by the acquisition of Allergan, while Humira sales faced erosion due to patent loss and biosimilar competition.

4 reports, 2 independent Updated Jun 28
Gone quiet
Reports
4
Developments
5
Repetition
25%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

AbbVie's product portfolio was bolstered by the acquisition of Allergan, while Humira sales faced erosion due to patent loss and biosimilar competition.

Who's involved

What this event is mainly about
AbbVieHUMIRAAllergan (United Kingdom)Europe

How it developed

Newest first. Tap a step to see who reported it.
  1. New acquisition strengthens AbbVie's presence in the dermatology market.1 source
  2. AbbVie's Humira is losing exclusivity and facing intense competition from Skyrizi and Rinvoq.Sub-event
  3. AbbVie's product portfolio was bolstered by the acquisition of Allergan, while Humira sales faced erosion due to patent loss and biosimilar competition.Sub-event
  4. AbbVie acquired Allergan and Humira sales declined due to biosimilar competition.1 source
  5. Patent protection for Humira was lost in Europe and the United States following the Allergan acquisition.

Keep exploring

Part of

AbbVie's product portfolio was bolstered by the acquisition of Allergan, while Humira sales faced erosion due to patent loss and biosimilar competition. All 1 developments

Within AbbVie's product portfolio was bolstered by the acquisition of Allergan, while Humira sales faced erosion due to patent loss and biosimilar competition.

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • yahoo.com
  • ZacksABBV or BMY: Which Biopharma Giant Has Better Prospects for Now? AbbVie, Inc. ABBV and Bristol Myers Squibb BMY are leading drugmakers with broad and diverse portfolios and a global footprint. AbbVie
  • Unknown outlet
  • Unknown outlet